Abstract
The greatest challenge in the postgenomic era is the description of proteome interactions, such as protein–protein or protein–DNA interactions. Surface plasmon resonance (SPR) is an optical technique in which binding of an analyte to the surface changes the refractive index at the surface/solution interface. Molecular interactions are analysed in real time without a labeling step. Currently, the limit to SPR imaging is the small number of reactions that can be simultaneously analysed. Using a novel grafting technology and a new imaging system, we increased the throughput of SPR imaging. The interaction between p53 and DNA was chosen as a paradigm for validation of this assay. Using a tagged DNA methodology, we simultaneously targeted multiple DNA sequences on a single chip. The interaction between p53 and these DNA sequences was monitored by SPR imaging. Qualitative and quantitative analysis provides results similar to those obtained with conventional technologies.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Balagurumoorthy P, Sakamoto H, Lewis MS, Zambrano N, Clore GM, Gronenborn AM, Appella E and Harrington RE . (1995). Proc. Natl. Acad. Sci. USA, 92, 8591–8595.
Bergamaschi D, Gasco M, Hiller L, Sullivan A, Syed N, Trigiante G, Yulug I, Merlano M, Numico G, Comino A, Attard M, Reelfs O, Gusterson B, Bell AK, Heath V, Tavassoli M, Farrell PJ, Smith P, Lu X and Crook T . (2003). Cancer Cell, 3, 387–402.
Deppert W, Gohler T, Koga H and Kim E . (2000). J. Cell. Biochem. Suppl., (Suppl 35), 115–122.
Dong SM, Traverso G, Johnson C, Geng L, Favis R, Boynton K, Hibi K, Goodman SN, D’Allessio M, Paty P, Hamilton SR, Sidransky D, Barany F, Levin B, Shuber A, Kinzler KW, Vogelstein B and Jen J . (2001). J. Natl. Cancer Inst., 93, 858–865.
Drewes G and Bouwmeester T . (2003). Curr. Opin. Cell. Biol., 15, 199–205.
El-Deiry WS, Kern SE, Pientenpol JA, Kinzler KW and Vogelstein B . (1992). Nat. Genet., 1, 45–49.
Favis R, Day JP, Gerry NP, Phelan C, Narod S and Barany F . (2000). Nat. Biotechnol., 18, 561–564.
Fried M and Crothers DM . (1981). Nucleic Acids Res., 9, 6505–6525.
Friedlander P, Haupt Y, Prives C and Oren M . (1996). Mol. Cell. Biol., 16, 4961–4971.
Galas DJ and Schmitz A . (1978). Nucleic Acids Res., 5, 3157–3170.
Gerry NP, Witowski NE, Day J, Hammer RP, Barany G and Barany F . (1999). J. Mol. Biol., 292, 251–262.
Guedon P, Livache T, Martin F, Lesbre F, Roget A, Bidan G and Levy Y . (2000). Anal. Chem., 72, 6003–6009.
Halazonetis TD, Davis LJ and Kandil AN . (1993). EMBO J., 12, 1021–1028.
Hansen S, Hupp TR and Lane DP . (1996). J. Biol. Chem., 271, 3917–3924.
Inga A, Storici F, Darden TA and Resnick MA . (2002). Mol. Cell. Biol., 22, 8612–8625.
Irwin MS, Kondo K, Marin MC, Cheng LS, Hahn WC and Kaelin WG . (2003). Cancer Cell, 3, 403–410.
Kato S, Han SY, Liu W, Otsuka K, Shibata H, Kanamaru R and Ishioka C . (2003). Proc. Natl. Acad. Sci. USA, 100, 8424–8429.
Kim E and Deppert W . (2003). Biochem. Cell. Biol., 81, 141–150.
Livache T, Maillart E, Lassalle N, Mailley P, Corso B, Guedon P, Roget A and Levy Y . (2003). J. Pharm. Biomed. Anal., 32, 687–696.
Melino G, De Laurenzi V and Vousden KH . (2002). Nat. Rev. Cancer, 2, 605–615.
Muller BF, Paulsen D and Deppert W . (1996). Oncogene, 12, 1941–1952.
Qian H, Wang T, Naumovski L, Lopez CD and Brachmann RK . (2002). Oncogene, 21, 7901–7911.
Resnick MA and Inga A . (2003). Proc. Natl. Acad. Sci. USA, 100, 9934–9939.
Rich RL and Myszka DG . (2000). Curr. Opin. Biotechnol., 11, 54–61.
Rowan S, Ludwig RL, Haupt Y, Bates S, Lu X, Oren M and Vousden KH . (1996). EMBO J., 15, 827–838.
Samuels-Lev Y, O’Connor DJ, Bergamaschi D, Trigiante G, Hsieh JK, Zhong S, Campargue I, Naumovski L, Crook T and Lu X . (2001). Mol. Cell, 8, 781–794.
Soussi T and Béroud C . (2001). Nat. Rev. Cancer, 1, 233–240.
Soussi T and Béroud C . (2003). Hum. Mutat., 21, 192–200.
Tokino T, Thiagalingam S, El -Deiry WS, Waldman T, Kinzler KW and Vogelstein B . (1994). Hum. Mol. Gen., 3, 1357–1542.
Vogelstein B, Lane D and Levine AJ . (2000). Nature, 408, 307–310.
Vousden KH and Lu X . (2002). Nat. Rev. Cancer, 2, 594–604.
Walhout AJ and Vidal M . (2001). Nat. Rev. Mol. Cell. Biol., 2, 55–62.
Acknowledgements
This work was supported by grants from the Association de la Recherche sur le Cancer (TS No. 4809), Ligue Nationale Contre le Cancer (Comité de Paris), the European Community's Fifth Framework Programme (QLRT-1999-00273), and Université PM Curie to TS. DC was supported by a fellowship from the Association de la Recherche sur le Cancer.
Author information
Authors and Affiliations
Corresponding author
Additional information
Supplementary Information accompanies the paper on Oncogene website (http://www.nature.com/onc)
Supplementary information
Rights and permissions
About this article
Cite this article
Maillart, E., Brengel-Pesce, K., Capela, D. et al. Versatile analysis of multiple macromolecular interactions by SPR imaging: application to p53 and DNA interaction. Oncogene 23, 5543–5550 (2004). https://doi.org/10.1038/sj.onc.1207639
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1207639
Keywords
This article is cited by
-
A novel molecular rotor facilitates detection of p53-DNA interactions using the Fluorescent Intercalator Displacement Assay
Scientific Reports (2018)
-
Fano Resonances in Thin Metallic Grating for Refractive Index Sensing with High Figure of Merit
Plasmonics (2016)
-
Enhanced SPR Sensitivity with Nano-Micro-Ribbon Grating—an Exhaustive Simulation Mapping
Plasmonics (2014)
-
Plasmonic DNA: Towards Genetic Diagnosis Chips
Plasmonics (2007)
-
SPR imaging as a tool for detecting mucin – anti-mucin interaction. Outline of the development of a sensor for near-patient testing for mucin
Microchimica Acta (2007)